Investors

Investor Relations

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of new inhalation products for the treatment of chronic respiratory diseases and lung conditions. In early testing, the Thin Film Freezing (TFF) proprietary platform significantly improved the solubility of drugs that have poor water solubility.

In 2021, TFF Pharmaceuticals hosted two conversations with Key Opinion Leaders to discuss its programs and potential of the Thin Film Freezing technology platform:

  • Learn more about TFF’s Inhaled Tacrolimus Powder to prevent immunosuppression from lung transplant as well as applications of Thin Film Freezing technology for vaccine applications in the webcast and presentation here.
  • Learn more about TFF’s Inhaled Voriconazole Powder to treat invasive pulmonary aspergillosis and the inhaled formulation of AUG-3387, a monoclonal antibody to prevent COVID-19, at the link here.

To learn more about TFF’s Thin Film Freezing technology, its lead programs, TFF Voriconazole and TFF Tacrolimus, and its broad-reaching partnering strategy, see the videos below.

TFF Pharmaceuticals Corporate Overview – March 2020


2021 Virtual Annual Meeting of Stockholders

 

Volume:

Data Provided by Refinitiv. Minimum 15 minutes delayed.


Press Releases

July 14, 2022
New Facility in Austin Will Enable Increased Capacity for Internal Pipeline Assets While Accommodating Growing Interest in Partnered Projects Significantly Increases Manufacturing Capabilities to Further Expand Thin Film Freezing Applications FORT WORTH, Texas , July 14, 2022 (GLOBE NEWSWIRE) --
Top